Expression of Antioxidant Enzymes in Astrocytic Brain Tumors

Haapasalo, Hannu; Kyläniemi, Maarit; Paunu, Niina; Kinnula, Vuokko L.; Soini, Ylermi

doi:10.1111/j.1750-3639.2003.tb00015.x

Cited by 56 publications

(44 citation statements)

References 42 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SOD2 in carcinogenesis has been widely studied but remains ambiguous. As one of the major antioxidant enzymes, it was proved to inhibit growth of tumor cells in cultured cancer cells and experimental animal models (33)(34)(35)(36), but was upregulated in various solid tumors, including lung cancer (37)(38)(39)(40)(41)(42). Consistent with previous studies that found the increased SOD2 in lung tumors and in the sera of lung SCC patients (41,42), SOD2 was observed to be up-regulated in lung SCC tumors compared with corresponding normal lung tissues in our study.…”

Section: Discussionmentioning

confidence: 99%

Identification of Isocitrate Dehydrogenase 1 as a Potential Diagnostic and Prognostic Biomarker for Non-small Cell Lung Cancer by Proteomic Analysis

Tan

Jiang

Sun³

et al. 2012

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related death in the world because of its high morbidity and mortality. Approximately 1.2 million people are diagnosed with lung cancer all over the world per year. Despite the great progresses in cancer research over the last decades, lung cancer remains at a very low 5-year survival rate: 16% compared with 89% for breast cancer, 65% for colon cancer, and 100% for prostate cancer (1). Although lung cancer comprises only about 15% of new cancer diagnosis, it causes over 30% of all cancer-related deaths. Lung cancer is divided into two major clinicopathological classes: small cell lung cancer (ϳ15% of all lung cancer) and non-small-cell lung cancer (NSCLC, ϳ85%).1 The latter includes three major histological subtypes: squamous cell carcinoma (SCC, 40% of NSCLC), adenocarcinoma (AD, 40% of NSCLC), and large cell carcinoma (10% of NSCLC) (2). NSCLC is commonly treated with surgery, whereas small cell lung cancer usually responds better to chemotherapy and radiotherapy. For NSCLC, curative surgery is efficacious only in those who are diagnosed sufficiently early in the disease process. Unfortunately, more than 70% of the patients are diagnosed only at an advanced stage nowadays, which results in the loss of opportunity for curative surgical resection and poor prognosis. To improve the survival of patients with lung cancer, identifying reliable biomarkers for early diagnosis and prognosis prediction and monitoring treatment response remain urgently needed. Proteomic analysis, a powerful tool for global evaluation of protein expression, has been widely applied in cancer reFrom the

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of Isocitrate Dehydrogenase 1 as a Potential Diagnostic and Prognostic Biomarker for Non-small Cell Lung Cancer by Proteomic Analysis

Tan

Jiang

Sun³

et al. 2012

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

show abstract

“…This view is supported by in vivo analyses that correlate SOD2 overexpression with worse prognosis in solid tumors. Several reports have shown increased SOD2 levels in many malignancies, including lung [20,33], colorectal [16,36], gastric and esophageal [13,17], brain [9], oral [22] and skin carcinomas [32], often associated with metastasis and poor prognosis. In contrast, SOD2 reduction was also observed in prostatic carcinomas when compared to normal tissues [1,3].…”

Section: Discussionmentioning

confidence: 99%

Deregulated Expression of Superoxide Dismutase-2 Correlates with Different Stages of Cervical Neoplasia

et al. 2011

View full text Add to dashboard Cite

Abstract.Objective: Superoxide dismutase-2 (SOD2) is considered one of the most important antioxidant enzymes that regulate cellular redox state in normal and tumorigenic cells. Overexpression of this enzyme may be involved in carcinogenesis, particularly in lung, gastric, colorectal and breast cancer. Methods: In the present study, we have evaluated SOD2 protein levels by immunohistochemistry (IHC) in 331 cervical histological samples including 31 low-grade cervical intraepithelial neoplasia (LSIL), 51 high-grade cervical intraepithelial neoplasia (HSIL), 197 squamous cervical carcinomas (SCC) and 52 cervical adenocarcinomas (ADENO). Results: We observed that SOD2 staining increases with cervical disease severity. Intense SOD2 staining was found in 13% of LSIL, 25.5% of HSIL and 40% of SCC. Moreover, 65.4% of ADENO exhibited intense SOD2 staining. Conclusions: Differences in the expression of SOD2 could potentially be used as a biomarker for the characterization of different stages of cervical disease.

show abstract

“…Not only does downregulation of SOD-1 expression increases sensitivity of tumor cells to the cytotoxic agents (28) but the anticancer activity of some flavonoids has also been attributed to their ability to inhibit thioredoxin reductase (10). Importantly, SOD and TRX have been implicated in the pathogenesis of astrocytomas (40). Our findings that siRNA-mediated down-regulation of SOD-1 and TRX-1 in gliomas increases ROS generation and enhances sensitivity to kaempferolinduced apoptosis are consistent with previous reports that inhibition of SOD (7) and TRX (29) enhances sensitivity of tumor cells to ROS-generating anticancer agents.…”

Section: Discussionmentioning

confidence: 99%

Kaempferol induces apoptosis in glioblastoma cells through oxidative stress

Sharma

Joseph²,

Ghosh³

et al. 2007

Molecular Cancer Therapeutics

212

181

View full text Add to dashboard Cite

Despite recent advances in understanding molecular mechanisms involved in glioblastoma progression, the prognosis of the most malignant brain tumor continues to be dismal. Because the flavonoid kaempferol is known to suppress growth of a number of human malignancies, we investigated the effect of kaempferol on human glioblastoma cells. Kaempferol induced apoptosis in glioma cells by elevating intracellular oxidative stress. Heightened oxidative stress was characterized by an increased generation of reactive oxygen species (ROS) accompanied by a decrease in oxidant-scavenging agents such as superoxide dismutase (SOD-1) and thioredoxin (TRX-1). Knockdown of SOD-1 and TRX-1 expression by small interfering RNA (siRNA) increased ROS generation and sensitivity of glioma cells to kaempferol-induced apoptosis. Signs of apoptosis included decreased expression of Bcl-2 and altered mitochondrial membrane potential with elevated active caspase-3 and cleaved poly(ADP-ribose) polymerase expression. Plasma membrane potential and membrane fluidity were altered in kaempferol-treated cells. Kaempferol suppressed the expression of proinflammatory cytokine interleukin-6 and chemokines interleukin-8, monocyte chemoattractant protein-1, and regulated on activation, normal T-cell expressed and secreted. Kaempferol inhibited glioma cell migration in a ROS-dependent manner. Importantly, kaempferol potentiated the toxic effect of chemotherapeutic agent doxorubicin by amplifying ROS toxicity and decreasing the efflux of doxorubicin. Because the toxic effect of both kaempferol and doxorubicin was amplified when used in combination, this study raises the possibility of combinatorial therapy whose basis constitutes enhancing redox perturbation as a strategy to kill glioma cells. [Mol Cancer Ther 2007;6(9):2544 -53]

show abstract

Expression of Antioxidant Enzymes in Astrocytic Brain Tumors

Cited by 56 publications

References 42 publications

Identification of Isocitrate Dehydrogenase 1 as a Potential Diagnostic and Prognostic Biomarker for Non-small Cell Lung Cancer by Proteomic Analysis

Identification of Isocitrate Dehydrogenase 1 as a Potential Diagnostic and Prognostic Biomarker for Non-small Cell Lung Cancer by Proteomic Analysis

Deregulated Expression of Superoxide Dismutase-2 Correlates with Different Stages of Cervical Neoplasia

Kaempferol induces apoptosis in glioblastoma cells through oxidative stress

Contact Info

Product

Resources

About